Brookline initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $9 price target Quince is advancing its AIDE technology platform that allows for encapsulation of a drug into a patient’s own red blood cells, the analyst tells investors in a research note. The firm sees a favorable risk-reward as EryDex advances through the clinic.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics management to meet with Maxim Group
- Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial
- Quince Therapeutics presents safety data from ATTeST trial at CNS meeting
- Quince Therapeutics initiated with a Buy at Maxim
- Quince Therapeutics initiated with a Buy at Rodman & Renshaw